tetano
Editor, Senior Moderator
Vaccine. 2013 May 31. pii: S0264-410X(13)00685-3. doi: 10.1016/j.vaccine.2013.05.070. [Epub ahead of print]
MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system.
Puig-Barber? J, Natividad-Sancho A, Calabuig-P?rez J, Lluch-Rodrigo JA, Pastor-Villalba E, Mart?nez-?beda S, P?rez-Vilar S, D?ez-Domingo J.
Source
?rea de Investigaci?n en Vacunas, Centro Superior de Investigaci?n en Salud P?blica (CSISP), Valencia, Spain. Electronic address: puig_joa@gva.es.
Abstract
BACKGROUND:
Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted influenza vaccines in this age group are lacking.
METHODS:
We conducted a retrospective cohort study to estimate the comparative effectiveness of MF59-adjuvanted trivalent influenza vaccine (TIV) and virosomal-TIV for prevention of influenza hospitalization in adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2010-2011 influenza season. We used Cox regression models to assess comparative effectiveness; crude and adjusted by age, sex, comorbidity, deprivation, type of insurance, and travel time to hospital. We accounted for data clustering at the hospital level by using a multilevel random effects model.
RESULTS:
Overall, 373,798 vaccinated subjects were evaluated. There were 40 hospitalizations for influenza among 176,618 subjects, contributing 4,288,109 person-weeks at risk in the virosomal-TIV group, and 37 hospitalizations for influenza among 197,180 subjects, contributing 4,786,360 person-weeks at risk in the MF59-TIV group. The crude hazard ratio (HR) was 0.83 (0.53-1.30), and the adjusted Cox estimated HR of MF59-TIV relative to virosomal-TIV was 0.86 (0.55-1.35). After accounting for data clustering, the HR of influenza hospitalization associated with MF59-TIV relative to virosomal-TIV was 0.94 (0.37-2.38).
CONCLUSION:
During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.
Copyright ? 2013. Published by Elsevier Ltd.
PMID:
23731629
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23731629
MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system.
Puig-Barber? J, Natividad-Sancho A, Calabuig-P?rez J, Lluch-Rodrigo JA, Pastor-Villalba E, Mart?nez-?beda S, P?rez-Vilar S, D?ez-Domingo J.
Source
?rea de Investigaci?n en Vacunas, Centro Superior de Investigaci?n en Salud P?blica (CSISP), Valencia, Spain. Electronic address: puig_joa@gva.es.
Abstract
BACKGROUND:
Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted influenza vaccines in this age group are lacking.
METHODS:
We conducted a retrospective cohort study to estimate the comparative effectiveness of MF59-adjuvanted trivalent influenza vaccine (TIV) and virosomal-TIV for prevention of influenza hospitalization in adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2010-2011 influenza season. We used Cox regression models to assess comparative effectiveness; crude and adjusted by age, sex, comorbidity, deprivation, type of insurance, and travel time to hospital. We accounted for data clustering at the hospital level by using a multilevel random effects model.
RESULTS:
Overall, 373,798 vaccinated subjects were evaluated. There were 40 hospitalizations for influenza among 176,618 subjects, contributing 4,288,109 person-weeks at risk in the virosomal-TIV group, and 37 hospitalizations for influenza among 197,180 subjects, contributing 4,786,360 person-weeks at risk in the MF59-TIV group. The crude hazard ratio (HR) was 0.83 (0.53-1.30), and the adjusted Cox estimated HR of MF59-TIV relative to virosomal-TIV was 0.86 (0.55-1.35). After accounting for data clustering, the HR of influenza hospitalization associated with MF59-TIV relative to virosomal-TIV was 0.94 (0.37-2.38).
CONCLUSION:
During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.
Copyright ? 2013. Published by Elsevier Ltd.
PMID:
23731629
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23731629